Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21645558 | 1.00 | CASP3 (0.50) | CASP3KMT2AL3MBTL1CTRB1CYP3A4 | |
| SCHEMBL2481578 | 1.00 | CASP3 (0.50) | CASP3KMT2AL3MBTL1CTRB1CYP3A4 | |
| SCHEMBL19022491 | 0.91 | PTPN1 (0.48) | CASP3KMT2AL3MBTL1CYP3A4MAPK1 | |
| SCHEMBL19022495 | 0.91 | PTPN1 (0.48) | CASP3KMT2AL3MBTL1CYP3A4MAPK1 | |
| SCHEMBL31520511 | 0.91 | MDM2 (0.47) | CASP3KMT2AL3MBTL1MDM4TP53 | |
| SCHEMBL31520506 | 0.91 | KMT2A (0.46) | CASP3KMT2AL3MBTL1MDM4TP53 | |
| SCHEMBL31520505 | 0.90 | CASP3 (0.48) | CASP3KMT2ACTRB1MDM4TP53 | |
| SCHEMBL6520211 | 0.90 | KMT2A (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29400883 | 0.90 | KMT2A (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119383 | 0.89 | CASP3 (0.57) | CASP3KMT2ACTRB1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | claimed |
| WO-2026107423-A1 | ORAL PEPTIDES AND USES THEREOF FOR WEIGHT LOSS, WEIGHT MAINTENANCE, AND MANAGEMENT OF METABOLIC CONDITIONS | METSERA, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2025019172-A1 | ANTIMICROBIAL EXTRACTANT FORMED FROM COPPER-CONTAINING SOURCE | CORNING INCORPORATED (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-4370530-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4146249-A1 | IMPROVED PROCESS FOR THE PREPARATION OF SEMAGLUTIDE | Neuland Laboratories Ltd (IN) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023288213-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2020027737-A1 | A SOLID-SUPPORTED HYDROXY AMINO ACID AND A SOLID-SUPPORTED AMINO ALCOHOL | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-02-06 | — | — | WO | disclosed |
| US-8717565-B2 | Optically active functional fluid markers | THE LUBRIZOL CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2376894-A1 | OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS | The Lubrizol Corporation (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2373977-A1 | OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS | The Lubrizol Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| EP-1675824-B1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | WURSTER SIEGFRIED (FI) | 2010-09-29 | — | — | EP | disclosed |
| WO-2010077753-A1 | OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS | THE LUBRIZOL CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077754-A1 | OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS | THE LUBRIZOL CORPORATION (US) | 2010-07-08 | — | — | WO | disclosed |
| US-7741362-B2 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SIEGFRIED WURSTER (FI) | 2010-06-22 | — | — | US | disclosed |
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | OY JUVANTIA PHARMA LTD (FI) | 2007-06-07 | — | — | US | disclosed |
| EP-1675824-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | Oy Juvantia Pharma Ltd (FI) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033068-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033069-A1 | SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS | OY JUVANTIA PHARMA LTD (FI) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129422-A1 | Somatostatin receptor 1 and/or 4 selective agonists and antagonists | SSTR4, SSTR1, SSTR3 | CASP3 3423/4885KMT2A 2112/4885L3MBTL1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.